DailyIQ
|
Sector:HealthcareAll sectors
Last updated 5 minutes ago

TECH·Bio-Techne Corporation

$.
+. (+.%)
After Hours
High
$71.39
Open
$71.08
Market Cap
11.15B
52W High
$72.16
Low
$70.84
P. Close
$71.29
P/E
102.76
52W Low
$43.20
Fwd P/E
34.86
DailyIQ Est.
$70.69
Technical Score (1D)
91
BUY
News Sentiment
54
MIXED
RBC Capital has downgraded Bio‑Techne to Sector Perform while lifting the price target to $73, a move that signals a more conservative view on near‑term valuation but still supports long‑term upside. The downgrade reflects concerns that current earnings momentum may not sustain, yet the higher target underscores confidence in the company’s pipeline and market positioning. In parallel, Bio‑Techne announced the addition of heat‑stable and hyperactive AI‑engineered designer proteins to its R&D Systems portfolio, targeting improved stability and activity in cell‑culture and cell‑therapy workflows. The new proteins are expected to enhance reproducibility and performance for researchers, potentially expanding TECH’s share of the life‑science tools market over the next 12–18 months. Evercore ISI’s recent downgrade to In‑Line, coupled with concerns over earnings growth and margin pressure, highlights the need to monitor the upcoming Q2 earnings release for guidance on revenue mix and cost control. Meanwhile, Merck KGaA’s all‑cash $11.5 billion acquisition of Bio‑Techne, approved by the board and pending regulatory review, introduces a significant strategic shift that could drive synergies and earnings accretion once closed. The acquisition’s regulatory clearance and integration progress will be key watch items, as they could materially alter the company’s valuation and growth trajectory. Analysts across the spectrum—RBC, Evercore, TD Cowen, Benchmark, Citigroup, and Deutsche Bank—have all adjusted ratings or targets, largely converging on a $73 price target but diverging on short‑term valuation concerns. Traders should therefore focus on the upcoming earnings guidance, regulatory updates on the Merck deal, and any product launch milestones that could validate the expanded AI‑engineered portfolio’s revenue impact.
Earnings Summary
Bio‑Techne Corporation is a global provider of life science reagents, instruments, and services, split between Protein Sciences and Diagnostics & Spatial Biology segments that support research, diagnostics, and bioprocessing markets; the company’s portfolio underpins cell and gene therapy development and regulated diagnostics, positioning it as a key supplier in the expanding life‑sciences sector. In the last two quarters, the firm reported EPS of $0.53 in Q2 2025 and $0.42 in Q3 2025, compared to $0.56 in Q1 2025 and $0.42 in Q4 2024, while revenue rose from $316.181 million to $316.964 million, then fell to $286.555 million, indicating a recent dip; the company beat consensus estimates in three of the last four quarters, with EPS exceeding guidance in Q4 2024, Q1 2025, and Q2 2025, but missing in Q3 2025 and Q2 2026. Over the past several quarters, Bio‑Techne has shown a mixed YoY revenue trajectory, with growth in Q1 and Q2 2025 but a decline in Q3 2025, and EPS growth that has outpaced revenue in some periods, reflecting the company’s focus on high‑margin contract services; the pattern of earnings surprises has been inconsistent, underscoring the impact of contract mix on profitability. Recent analyst commentary highlights a shift in sentiment, with Evercore downgrading the stock to in‑line amid concerns over near‑term earnings growth and margin pressure, while Piper Sandler upgraded the target price to $73 from $60, signaling confidence in a stronger earnings outlook; TD Cowen’s downgrade to hold reflects valuation concerns despite a higher target, suggesting a cautious view of short‑term upside. Investors should watch the upcoming Q4 2026 earnings release for guidance on revenue and margin trends, monitor any updates on the contract‑service revenue mix and product‑pipeline developments that could influence earnings, and keep an eye on broader biotech market sentiment that may amplify the impact of analyst revisions.

EPS

EstBeatMiss
$0.40$0.44$0.49$0.54$0.58Q1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$0.52 - -
Q3'26$0.53$0.53-0.8%
Q2'26$0.54$0.46-14.5%
Q3'25$0.42$0.42-0.4%
Q2'25$0.50$0.53+5.8%
Q1'25$0.51$0.56+10.4%

Revenue

EstBeatMiss
$281M$293M$304M$315M$326MQ1'25Q2'25Q3'25Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$321M - -
Q3'26$316M$311M-1.5%
Q2'26$317M$296M-6.5%
Q3'25 - $287M -
Q2'25 - $317M -
Q1'25 - $316M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

TECH Stock Snapshot

TECH is currently trading at $71.30, giving Bio-Techne Corporation a market cap of 11.15B and a P/E ratio of 102.8. Today's range spans $70.84–$71.39, with shares opening at $71.08 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 54/100.

Over the past year TECH has traded between $43.20 and $72.16 - the current price is +65.0% off the 52-week low and -1.2% from the high. 25 analysts cover the stock with a Hold consensus and a mean 12-month target of $70.00 (range $50.00–$73.00), implying downside of -1.8%.

The Healthcare sector has plenty of names, but TECH is one of the few right now where technical and sentiment data are both bullish. Score: 91/100 (BUY). Sentiment: neutral (54/100). Price: $71.30 (near 52-week highs). The current P/E ratio stands at 102.8. With 11.15B in market cap, this is the scale where fundamental thesis and technical setup reinforce rather than compete with each other. Annual range: $43.20–$72.16.

What makes TECH's BUY setup (91/100) particularly actionable at 11.15B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $71.30 (near 52-week highs in $43.20–$72.16), with sentiment running neutral at 54/100, the setup rewards conviction-sized positioning more than it does speculative small bets.